Sofia Fund News

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease

Mutation Validates Cognition Approach to Oligomer Displacement

Pittsburgh, October 19, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower Binding Affinity than Wild-Type Peptide,” has been published online in the Journal of Neurochemistry (doi:10.1111/jnc.15212).…

Joylux Founder, Colette Courtion, Named to Inc.’s Female Founders 100 list

Seattle, WA October 13, 2020 — Inc. today announced its third annual Female Founders 100 list, honoring an influential, ambitious, and diverse group of 100 women who are building America’s most inspiring and innovative businesses. Colette Courtion, the founder of Joylux, a platform of life-changing solutions for menopausal women, is proud to be acknowledged in this prestigious list of female founders.…

Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study

Pittsburgh, August 27, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease.…

Cognition Therapeutics Receives $75.8 Million NIA Grant

Sofia portfolio company Cognition Therapeutics awarded $75.8M in competitive grant process, to study efficacy of its technology with early Alzheimer’s patients

New York, June 08, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected to total $75.8 million over five years to support a 540-patient Phase 2 study of CT1812 in individuals with early Alzheimer’s disease.…